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Abstract
Background: Traveling to Tibet implies a risk for developing acute mountain sickness (AMS), and the size of this
problem is likely increasing due to the rising number of tourists. No previous study on AMS has been conducted
among the general tourist population in Tibet. Thus, the aim of this study was to estimate the prevalence and
determinants of AMS in a large tourist population visiting Lhasa.
Methods: A sample of 2385 tourists was recruited from seven randomly selected hotels in Lhasa between June
and October 2010. Within three days of their first arrival, the participants filled in a questionnaire based on the
Lake Louise Scoring System (LLSS) about AMS-related symptoms and potential contributing factors. AMS was
defined as the presence of headache and a cumulative Lake Louise Score ≥4. After estimating the prevalence
of AMS, a Log-Binomial Model was applied to analyse the relationship between AMS and selected risk factors.
Results: The prevalence of AMS was 36.7 % (95 % CI: 34.6–38.7 %) and was not dependent on tourists’ country of
origin. Among the participants who developed AMS, 47.6 % reported that they experienced symptoms within the
first 12 h after arriving in Lhasa, and 79.0 % reported that they had to reduce their activity level. A poor or average
health condition (adjusted PR 1.63, 95 % CI 1.38–1.93), an age below 55 years (adjusted PR 1.29, 95 % CI 1.04–1.60), a
rapid ascent to Lhasa (adjusted PR 1.17, 95 % CI 1.02–1.34) were independent AMS risk factors, while smoking
(adjusted PR 0.75, 95 % CI 0.59–0.96) and pre-exposure to high altitude (adjusted PR 0.71, 95 % CI 0.60–0.84)
reduced the risk of AMS.
Conclusions: AMS is commonly experienced by tourists visiting Lhasa Tibet, and often affects their activities.
The tourists’ country of origin did not seem to affect their risk of AMS, and their age was inversely related to
AMS. Subjects planning to visit a high-altitude area should be prepared for experiencing AMS-related problems, and
consider preventive measures such as pre-exposure or a gradual ascent to high altitudes.
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Background
Since the opening of the world’s highest plateau railway
(The Qinghai-Tibet Railway) to Lhasa in 2006, the num-
ber of tourists visiting Tibet has increased sharply from
2.5 million in 2006 to more than 15 million visitors in
2014 [1]. Tourism revenue accounted for over 20 % of
the region’s gross domestic product (GDP) in 2014 [1].
Tourists travelling to Tibet from low-altitude areas have
the potential risk of developing acute mountain sickness
(AMS) during the first few days due to exposure to
hypobaric hypoxia environment at high altitude [2].
AMS is usually characterized by symptoms of headache,
dizziness, vomiting, anorexia, fatigue and insomnia after
arrival at high altitudes [3]. In some serious cases, AMS
can progress to life-threatening high-altitude cerebral
edema (HACE) or high-altitude pulmonary edema
(HAPE) [4]. The prevalence of AMS after ascending to
high altitude has been reported to vary between 9 and
84 % [5–9]. There are few places where large numbers
of ordinary tourists can easily and rapidly reach altitudes
as high as in Lhasa (3658 m above sea level). A recent
study reported that 51 % of construction workers experi-
enced AMS upon first-time exposure to high altitude on
the Qinghai-Tibet railroad route [10]. In addition, 57 %
of army recruits who travel from the lowlands to Lhasa
by air developed AMS [11]. These studies were carried
out in quite homogenous populations, primarily consist-
ing of young participants in presumably good health,
which is probably different from what one would expect
to be the case among ordinary tourists visiting Lhasa
nowadays. Data on AMS among ordinary tourists is
scarce. More knowledge about AMS among tourists
travelling to high altitude could be important for persons
planning to go there, as well as for professionals taking
care of them both before and after arrival at such alti-
tudes. The present study aimed to estimate the preva-
lence of AMS and to identify the determinants for
developing AMS in an adult population of ordinary tour-
ists visiting Lhasa Tibet China.
Methods
Ethics
The Ministry of Health and the Tibet University Medical
College in TAR approved the research. The study
protocol was submitted to the Norwegian National
Committee for Medical and Health Research Ethics,
which found the study unnecessary to undergo evalu-
ation since the collected information was considered
anonymous. Information about the details of the
study was given on the first page of the questionnaire.
The potential participants were also informed that the
study was voluntarily and anonymous, and that they
could refuse to participate without any negative
consequences.
Setting
The data collection was carried out in Lhasa, the capital
city of the Tibet Autonomous Region (TAR). The eleva-
tion of Lhasa makes it one of the highest situated cities
in the world [1]. Lhasa is a sacred city situated in the
Himalayas and attractive for many types of tourists.
There were 90 star-rated hotels and a few guest houses
in Lhasa at the time of the data collection [12].
Study samples
Nine hotels were randomly selected to participate in the
study from a list covering all hotels in Lhasa which was
given by the local tourism bureau. The management of
the hotels were informed about the study and asked if
they were willing to participate. All hotels agreed to par-
ticipate, but the managers of two of the hotels decided
to withdraw from the study when the data collection
started. Thus, in seven hotels, tourists older than 15 years
of age were invited to participate in the present study
between 2 June and 31 October 2010. Receptionists from
the selected hotels were given instructions in how to in-
form participants about the study, all aspects of the data
collection as well as how to act in case study participants
were in need of support for AMS related problems.
Tourists received a questionnaire and instructions about
the criteria needed for participation (age >15 years; clas-
sified as a tourist), and how to fill in information and re-
turn the questionnaire before leaving the hotel,
depending on the duration of their stay at the hotel. This
meant that the questionnaire was to be returned to the
receptionist the third night after their arrival, or on the
day when they checked out if the tourists planned to
stay two nights or less. In total, 2385 tourists were in-
vited to participate during the data collection period and
all returned the questionnaire. It turned out that 106 of
the tourists refused to participate, and handed in their
questionnaire without information. The lack of an un-
derstanding Chinese and English and limited time were
the main reasons for refusing to participate. Further-
more, 76 participants were excluded due to incomplete
questionnaire information, non-tourist status or an age
below 15 years, leaving 2203 participants (92.4 %) for
the analyses.
Variables
The questionnaire was tested in a pilot study in 2008,
and a revised version was available for the current study
in both Chinese and English. The questionnaire was de-
signed to obtain data concerning age, gender, height,
weight, altitude of permanent residence, nationality, edu-
cation, type of transport to Lhasa (by plane, by train, by
bus or by car), previous exposure to high altitude, prior
history of high-altitude illness, the use of prophylactic
medicine, smoking habits, awareness of altitude sickness
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and self-reported health condition. Body Mass Index
(BMI) was calculated as body weight (kg) divided by
height (m) squared. According to the World Health
Organization (WHO), obesity was categorized by
BMI ≥ 30.00.
AMS was assessed by the Lake Louise Score System
(LLSS) [13], which is based on the most frequent symp-
toms considered important for AMS: headache, dizzi-
ness, gastrointestinal distress (loss of appetite, nausea, or
vomiting), lassitude or fatigue and insomnia [14]. Each
item is scored by the subject on a scale between 0 and 3
(0 = none, 1 = mild, 2 =moderate, 3 = severe). Single item
scores are added up, with the total scores ranging from a
minimum of 0 to a maximum of 15. Headaches have
been recognized as a key symptom of AMS by previous
researchers [15–17]. AMS was defined as the presence
of a headache, at least one other symptom and a total
LLS ≥4 [14].
Statistical analysis
The Log-Binomial Model was applied to analyse the re-
lationship between AMS and selected risk factors. The
crude and adjusted prevalence ratio (PR) was computed
with 95 % confidence intervals (Cl), level of statistical
significance was set at p < 0.05. The analyses were
carried out using SPSS (Statistical Package for Social




The participants originated from 48 different countries.
The largest group was from China (46.9 %), followed by
the Netherlands (6.3 %), the US (5.8 %), Germany
(4.8 %), France (3.7 %) and the United Kingdom (3.7 %).
Population characteristics are given in Table 1, and there
was an approximately equal representation of men and
women, and the mean age was 37.2 ± 14.4 years (range
15–81 years). Most of the tourists were non-obese, lived
at low altitudes, non-smokers and considered themselves
to be in good health. Almost half of the participants
took prophylactic medicine. Among them, 72.6 % took
Rhodiola or other Chinese medicine, 25.3 % used acetazol-
amide or diamox and 2.1 % used steroids or nifedipin.
More than one-third of the participants reported previous
AMS symptoms, and 25.6 % had been exposed to high al-
titudes in the preceding three months. Some tourists re-
ported to have diabetes mellitus (n = 30;1.4 %), high
blood pressure (n = 112;5.3 %), cardio-vascular disease
(n = 25;1.2 %) or lung diseases (n = 90;4.3 %).
Acute mountain sickness
A total of 808 (36.7 %, CI: 34.6–38.7 %) subjects reached
the standard of AMS with headache and a total LLS ≥ 4.
Table 1 also shows the prevalence of AMS in different
subgroups of the population, as well as crude and ad-
justed prevalence ratios for the potential determinants of
AMS. Different approaches of analyses yielded similar
results: analyses based on including all determinants in
the model, specific causal models for each of the vari-
ables and models that only included variables that were
statistically significantly related to AMS in the crude
analyses. Only results from the first approach are re-
ported in the present study, and we did not find any
substantial differences in AMS prevalence between
Chinese and other nationalities. Further stratification into
participants from Asia, Europe, America and Oceania did
not show a substantial variation in AMS prevalence either.
Moreover, we did not find contrasts in prevalences of
AMS between users and none users of prophylactic medi-
cine. That was also the case for subgroups of participants
who used Rhodiola, acetazolamide, steroids and nifedipin
(results not given). In the fully adjusted model, the factors
that remained statistically significantly associated with a
higher risk of AMS were a poor or average health condi-
tion, no pre-exposure to high altitude, an age below
55 years, being a non-smoker and arrival in Lhasa by air.
A total of 1808 participants (82.1 %) reported at least
one of the recorded symptoms. Fatigue was the most fre-
quently reported symptom, followed by headache, in-
somnia, dizziness and gastrointestinal symptoms (Fig. 1).
The mean overall AMS scores were 3.34 ± 2.63. In sub-
groups among those both with and without AMS, the
mean scores differed significantly (p < 0.05), 5.94 ± 1.92
and 1.68 ± 1.40, respectively. In 30.5 % of participants,
the onset of AMS symptoms started as early as on the
journey to Lhasa, while in 47.6 % of participants the
symptoms started within the first 12 h after arrival and
in 21.9 % after 12 h. Furthermore, 21.0 % of the partici-
pants with AMS did not reduce their physical activity
and 74.0 % had a moderate activity reduction, while
5.0 % chose to rest in bed because of symptoms. A total
of 282 participants reported to have sought help or ad-
vice for AMS. Among them, 150 (53.2 %) got help from
their tour companions or local friends, 92 (32.6 %) went
to local hospitals and 20 (7.1 %) received a visit by the
local doctor. No cases of HACE or HAPE were reported
among the participants during the three days follow up.
Discussion
AMS defined as LLS ≥ 4 with headache was reported
by 36.7 % of the participants. Fatigue, headache and
insomnia were the three most commonly reported
AMS related symptoms (66.8, 60.4 and 56.3 %, re-
spectively). Tourists who reported to not be in a good
health condition, to have no pre-exposure at high alti-
tude in the preceding three months, to be younger
than 55 years of age, to be a non-smoker and to have
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Table 1 Characteristics, prevalence and risk factors of acute mountain sickness among tourists above 15 years of age arriving in
Lhasa, Tibet, China between June and October 2010
Characteristics N AMS+ Crude PR Adjusted PR*
N (%) (95 % CI) (95 % CI)
Gender
Female 1072 387 (36.1) 1 1
Male 1103 461 (41.8) 1.16 (1.04,1.29) 1.08 (0.94,1.23)
Age
≥ 55 years 360 116 (32.2) 1 1
< 55 years 1796 722 (40.2) 1.25 (1.06,1.46) 1.29 (1.04,1.60)
Obesity
No 2015 787 (39.1) 1 1
Yes 119 48 (40.3) 1.03 (0.82,1.29) 1.02 (0.76,1.37)
Nationality
Chinese 1018 401 (39.4) 1 1
Other nationalities 1162 447 (38.5) 0.98 (0.88,1.09) 0.92 (0.78,1.08)
Altitude of permanent residence/home
2000 m or higher (>6500 ft) 111 37 (33.3) 1 1
Below 2000 m (<6500 ft) 1994 784 (39.3) 1.18 (0.90,1.54) 1.06 (0.76,1.49)
Education
College or higher 1766 701 (39.7) 1 1
High school or lower 361 130 (36.0) 1.10 (0.95,1.28) 1.11 (0.92,1.33)
Smoking
No 1849 742 (40.1) 1 1
Yes 251 83 (33.1) 0.76 (0.63,0.92) 0.75 (0.59,0.96)
Transportation
Not by air 1138 409 (35.9) 1 1
By air 1022 435 (42.6) 1.18 (1.07,1.32) 1.17 (1.02,1.34)
Health condition
Good health 1904 710 (37.3) 1 1
Poor or average health 197 117 (59.4) 1.59 (1.40,1.81) 1.63 (1.38,1.93)
Previous AMS symptoms
No 1011 361 (35.7) 1 1
Yes 590 221 (37.5) 1.05 (0.92,1.20) 1.10 (0.96,1.26)
Awareness of AMS
No 248 92 (37.1) 1 1
Yes 1851 732 (39.5) 0.94 (0.79,1.11) 1.02 (0.83,1.27)
Pre-exposure in the preceding 3 months
No 1609 695 (43.2) 1 1
Yes 552 148 (26.8) 0.62 (0.54,0.72) 0.71 (0.60,0.84)
Use of prophylactic
No 1116 416 (37.3) 1 1
Yes 965 399 (41.3) 1.11 (1.00,1.24) 1.05 (0.92,1.20)
*Adjusted for all variables in the table
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ascended to high altitude by air were at increased risk
of experiencing AMS.
To the best of our knowledge, no other study has ad-
dressed the prevalence and risk factors of AMS in a
large population of ordinary tourists arriving at an alti-
tude as high as that in Lhasa. Characteristics of tourists
visiting Lhasa will most likely change over time. We be-
lieve that the current study population resembled the
typical recreational tourists to Tibet during the data col-
lection period. The population showed a broad variation
in characteristics that might influence their risk of devel-
oping AMS.
AMS was definitely a common problem among the
study participants. Previous studies have reported both a
higher and lower prevalence of AMS than our finding
[6, 18–21]. Comparisons between studies are compli-
cated by differences in population characteristics [20],
altitude reached [6] and AMS definitions [18]. The
current AMS prevalence is lower than what was re-
ported in two other studies from Tibet, including one
among tourists (42.3 %) visiting the Namtso Lake at
4718 m in Tibet [22] and one among construction
workers (51 %) at Qinghai-Tibet altitudes up to 5000 m
[23]. The higher altitude in these two studies could ex-
plain the higher prevalence of AMS compared to our
study. The prevalence in our study was clearly higher
than in a study carried out among tourists (28 %) in La
Paz Bolivia at a similar altitude (3630 m) as that of
Lhasa, even if we used a stricter definition of AMS [24].
However, that study consisted of only 32 participants,
and AMS was measured immediately after arrival at high
altitude. Several studies have been conducted among
trekkers and mountaineers [8, 18, 20, 25, 26] with vary-
ing results. For example, one study showed a prevalence
of 34 % in mountaineers in the Alps [8], which is quite
comparable to our findings, while another study re-
ported a prevalence of 10 % in trekkers in the Nepali
Himalaya [18]. Overall, we believe that the prevalence
found in this study is of an expected size compared with
earlier studies if we attempt to take into account the dif-
ferences in study populations, the altitude reached and
the disease definition.
The unique culture and sacred places in Lhasa may
motivate a variety of tourists to go there. Based on our
observations, we cannot conclude that a population con-
sisting of ordinary tourists has a substantially higher risk
of AMS than more selected groups, even if there is rea-
son to believe that such a population is less healthy and
less physically fit compared to trekkers [11], mountain-
eers [25] and construction workers [10]. Our findings
support the idea that AMS symptoms typically appear
within the first 12 h after arrival at high altitude [3, 27,
28], and that people from different countries have a simi-
lar risk of developing AMS. In the present study, fatigue
was the most frequently reported symptom of AMS,
followed by headaches and sleep disorders. This is some-
what inconsistent with some earlier studies [16, 28, 29]
that reported headaches and sleep disorders to be more
common than fatigue. However, all these symptoms were
common and most tourists have to expect some AMS-
related symptoms and a reduction of activity during the
first days, in addition to a few who would also prefer to
stay in bed.
A lack of pre-exposure and rapid ascent to high
altitude have been linked to AMS in previous studies
[9, 11, 30–32]. For instance, Schneider and colleagues
[32] reported that altitude exposure in the preceding
two months reduces the risk of AMS. Hultgren and
colleagues [33] found climbers who visited the Himalayas
annually had fewer symptoms and improved their physical
Fig. 1 Prevalence of symptoms of acute mountain sickness by severity among tourists above 15 years of age arriving in Lhasa, Tibet, China
between June and October 2010
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performance compared with the first time they visited.
Our findings corroborate with this, and indicate some de-
gree of physiological acclimatization and residual benefit
from high-altitude exposure during the last three months.
Living at high altitude has also been found to protect
against AMS [6, 34]. Only a small proportion of the par-
ticipants in our study lived at an altitude above 2000 m.
Even if the AMS prevalence was low within this group, a
low statistical power made it difficult to draw firm conclu-
sions based on our findings. Several studies have shown
an increased risk of AMS with a rapid ascent to high alti-
tude [2, 3, 9]. Murdoch and colleagues found the preva-
lence of AMS to be 84 % among tourists who flew directly
to Shyangboche at the altitude of 3740 m compared with
61 % among those who walked up from altitudes under
3000 m to the same altitude [9]. Our findings support this
idea, as persons arriving by plane reported more frequent
AMS than others. It is a possibility that the chosen trans-
port to high altitude is related to a person’s risk of devel-
oping AMS. We have attempted to address this by
adjusting for an awareness of AMS and previous experi-
ence of AMS in the analyses. A further selection effect
would probably lead to an underestimation of the effect of
rapid ascent.
The impact of health conditions on the development
of AMS is of importance for individual’s decisions to
travel to high altitude, though the answer to this ques-
tion is unclear [6, 14, 31]. The prevalence of AMS was
similar between those with and without diseases such as
lung disease and cardio-vascular disease. This observa-
tion is in accordance with previous studies (18, 28, 29).
On the other hand, we found that those who reported
not being in good health had a higher risk of AMS. This
seeming inconsistency could be explained by subjective
reports of health condition by participants. Although
smoking is generally considered harmful to health, stud-
ies have not always confirmed this [35, 36]. For example,
Wu and colleagues [35] found that an 11 % decrease in
the prevalence of AMS in smokers compared with non-
smokers, whereas Song and colleagues [36] found that
the prevalence of AMS was lower in smokers than in
non-smokers. Our finding is in agreement with these
studies. The potential explanation could be that smoking
contributes to a reduction in nitric oxide (NO) [36], and
it has been speculated that reduced NO levels may pro-
tect smokers from some AMS related symptoms [35].
However, this phenomenon would probably only last for
a short period and perhaps reduce long-term adaptation
to high altitude [35].
Reports on the effect of gender on AMS have been
mixed and inconclusive [28, 37], as we did not find any
indication of gender differences with AMS. Some previ-
ous studies conducted among Himalayan trekkers [38],
conference attendees [6] and mountaineers [8] have
reported that age was inversely correlated with AMS.
Our findings corroborate with this. One theory [39]
about the relationship between age and susceptibility to
AMS is that there are age-dependent differences in
intracranial and intraspinal cerebrospinal fluid capacity
[40]. Old people with a larger ratio of cranial cerebro-
spinal fluid to brain volume results in them being better
able to compensate for brain swelling by a displacement
of cerebrospinal fluid, and are less likely to suffer from
AMS than young people with a lower ratio [40].
Since there were only a few other accommodations or
guest houses for tourists that were not on the tourist
bureau’s list, we have recruited participants from ran-
domly selected hotels that represent the absolute major-
ity of the places where tourists can stay in Lhasa. Most
of the tourists who were invited to participate in the
present study were willing to give the information that
was asked for. We do not see strong reasons as to why
AMS prevalence should be over- or underestimated in
the study population. A more general problem with all
such surveys is the potential selection mechanisms for
the visiting populations, which could influence preva-
lence of AMS and associations between exposure and
AMS. For example, it seems reasonable that people’s de-
cision not to go high could be affected by a previously
bad experience with AMS. We believe that our finding
of no negative effect of a former experience with AMS
could have been caused by self-selection. Such selection
processes could also affect other associations. It could be
that people in old age, people who do not take prophy-
lactic medicine, people with diseases, as well as smokers
who decide to go high are a “healthy” part of that expos-
ure group, and that such characteristics may change over
time and between populations. Consistency in findings
between different study populations with different char-
acteristics would be of help. However, there are reasons
for expecting differences between studies, so to draw
general causal claims from these types of studies is
therefore challenging. As a consequence, we believe that
our findings reflect conditions and relations among tour-
ists in Tibet recently, and if these findings corroborate well
with results from similar studies carried out elsewhere,
one could expand the interpretation of the findings.
Conclusion
AMS and AMS-related symptoms in tourists travelling
to Lhasa are common, and tourists often need to reduce
their activities during the first days of their stay. Symp-
toms typically start within the first 12 h after arriving.
Associations between risk factors and AMS could be af-
fected by self-selection in these types of studies. Age was
inversely related to AMS, while country of origin, gender
and reports of suffering from a chronic disease did not
seem to be predictors of AMS. Subjects planning to visit
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high-altitude areas should be prepared for experiencing
AMS-related problems, and consider preventive measures
such as pre-exposure or gradual ascent to high altitudes.
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